Clinical trials: Neoplasms, Germ Cell and Embryonal
Glioma, Brain Metastases, Adult
Revision of the EORTC QLQ-BN20 Questionnaire
Despite the fact that use of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Brain Neoplasm (QLQ-BN20) has tremendously contributed to insight into the health-related quality…
- Trial name
- QLQBN20 (NCT04689321)
- Testing
- No intervention
- Where
- Netherlands
- Volunteers
- 135 people
- Sponsor
- Leiden University Medical Center
Glioblastoma (GBM)
Combination Immunotherapy Treatment for Glioblastoma Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy
The objective of this study is to evaluate the safety, feasibility, and preliminary antitumor activity of this multi-component immunotherapy strategy in patients with advanced solid tumors.
- Trial name
- NCT07762716
- Testing
- BreakVax, Ipilimumab 2.5 mg, Pembrolizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- BreakBio Corp
Non Functioning Entero-pancreatic Endocrine Tumour
Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour
The primary purpose of this extension study was to assess the long term safety of patients with nonfunctioning enteropancreatic neuroendocrine tumour (NET), who were treated with open label lanreotide Autogel (120 mg every 28…
- Trial name
- NET729 (NCT00842348)
- Testing
- lanreotide (Autogel formulation)
- Where
- 25 sites in United States, Belgium and 7 more
- Volunteers
- 89 people
- Sponsor
- Ipsen
Brain Cancer
Diffuse Intrinsic Pontine Glioma (DIPG) Reirradiation (ReRT)
The goal of this clinical research study is to find a safe dose of radiation that can be given to patients with brainstem glioma who have already received radiation therapy. You will receive photon radiation therapy.
- Trial name
- NCT01469247
- Testing
- Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- M.D. Anderson Cancer Center
Anaplastic Astrocytoma, Anaplastic Astrocytoma, Not Otherwise Specified
Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma
This phase II trial studies how well the combination of dabrafenib and trametinib works after radiation therapy in children and young adults with high grade glioma who have a genetic change called BRAF V600 mutation.
- Conditions
- Anaplastic Astrocytoma, Anaplastic Astrocytoma, Not Otherwise Specified, Anaplastic Ganglioglioma, Anaplastic Pleomorphic Xanthoastrocytoma
- Trial name
- NCT03919071
- Testing
- Biospecimen Collection, Dabrafenib Mesylate, Lumbar Puncture
- Where
- 131 sites in United States, Puerto Rico
- Volunteers
- 58 people
- Sponsor
- National Cancer Institute (NCI)
Glioma, Glioblastoma
Sub-lobectomy for IDH Wild-type and TERT Promoter Mutant Glioblastoma
Glioblastoma is recognized as the most common and aggressive form of primary malignant brain tumor, with treatment options that are limited and prognosis that is extremely poor, showing median progression-free survival of 12…
- Trial name
- NCT06368934
- Testing
- sub-lobectomy, imaging total resection
- Where
- China
- Volunteers
- 326 people
- Sponsor
- Huashan Hospital
Chordoma
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Chordoma
This is an open-label, multicenter phase II study to evaluate the safety, efficacy and pharmacokinetic characteristics of BL-B01D1 for Injection in patients with locally advanced or metastatic chordoma.
- Trial name
- NCT06787664
- Testing
- BL-B01D1
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Glioma, Glioblastoma Multiforme
Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab
The goal of this interventional study is to evaluate the efficacy of APG-157 in combination with Bevacizumab in subjects with recurrent high-grade glioma.
- Trial name
- NCT06011109
- Testing
- APG-157
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Aveta Biomics, Inc.
Unresectable, Recurrent or Metastatic Melanoma, Untreated Mucosal or Acral Lentiginous Melanoma
A Study to Evaluate the Safety and Efficacy of MGD013 in Patients With Melanoma
This is an open-label, multi-cohort, multi-center Phase I clinical trial to evaluate the efficacy and safety of MGD013 in ① Cohort 1: patients with unresectable, recurrent or metastatic melanoma who have failed prior immune…
- Trial name
- NCT04653038
- Testing
- MGD013
- Where
- 13 sites in China
- Volunteers
- 92 people
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
Sarcoma
Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00006734
- Testing
- filgrastim, cyclophosphamide, doxorubicin hydrochloride
- Where
- 239 sites in United States, Australia and 5 more
- Volunteers
- 587 people
- Sponsor
- Children's Oncology Group
Melanoma (Skin)
CCI-779 in Treating Patients With Metastatic Melanoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of CCI-779 in treating patients who have metastatic…
- Trial name
- NCT00022464
- Testing
- temsirolimus
- Where
- 21 sites in United States, Canada
- Sponsor
- City of Hope Medical Center
Glioblastoma
Glioblastoma Targeted Treatment Option Maximization by WGS
In Dutch centers performing neurosurgery on and/or treating GBM, all recurrent GBM patients are discussed in local tumor boards and this setup will be used to effectively identify possible GLOW study candidates.
- Trial name
- GLOW (NCT05186064)
- Testing
- whole genome sequencing
- Where
- Netherlands
- Volunteers
- 164 people
- Sponsor
- UMC Utrecht
Melanoma, Skin Cancer
Melanoma Surveillance Photography (MSP) to Improve Early Detection of Melanoma in Ultra-high and High Risk Patients
This randomised controlled trial will investigate the role of melanoma surveillance photography (MSP) in the surveillance of patients at high or ultra-high risk of melanoma.
- Conditions
- Melanoma, Skin Cancer, Anxiety and Fear
- Trial name
- IMAGE (NCT04385732)
- Testing
- 2D or 3D Melanoma Surveillance Photography
- Where
- 12 sites in Australia
- Volunteers
- 670 people
- Sponsor
- Melanoma and Skin Cancer Trials Limited
Cognitive Side Effects of Cancer Therapy, Malignant Ovarian Epithelial Tumor
Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy
This clinical trial is studying changes in brain function in patients with stage I, stage II, stage III, or stage IV ovarian, primary peritoneal, or fallopian tube cancer who are receiving chemotherapy.
- Conditions
- Cognitive Side Effects of Cancer Therapy, Malignant Ovarian Epithelial Tumor, Ovarian Brenner Tumor, Ovarian Carcinosarcoma
- Trial name
- NCT01080521
- Testing
- Cognitive Assessment, Quality-of-Life Assessment
- Where
- 182 sites in United States
- Volunteers
- 247 people
- Sponsor
- Gynecologic Oncology Group
Glioma
Three miRNA Signatures in Glioma: From Molecular Mechanisms to Potential Clinical Application
Individual overexpression of the three miRNAs negatively affects cell viability and proliferation mainly in grade III IDH-wild type cells, while in higher grade cells, the effect is more pronounced when the entire signature is…
- Trial name
- NCT06883214
- Where
- Italy
- Volunteers
- 10 people
- Sponsor
- Regina Elena Cancer Institute
Stage II Cutaneous Melanoma
COmparison of the Use of a PERforator Flap Versus Total Skin GRAft in the Management of Loss of Substance After Resection of Cutaneous Melanoma - Pilot Study
Melanoma is an aggressive and potentially fatal skin cancer and was the fifth most commonly diagnosed cancer among both men and women in the United States in 2022.
- Trial name
- COPERGRAM1 (NCT07354152)
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Nantes University Hospital
Melanoma (Skin)
Vaccine Therapy in Treating Patients With Primary Stage II Melanoma
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. It is not yet known whether vaccine therapy is more effective than observation alone for melanoma.
- Trial name
- NCT00005052
- Testing
- GM2-KLH vaccine, QS21, adjuvant therapy
- Where
- 80 sites in Australia, Belgium and 16 more
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Lymphadenopathy, Stage I Testicular Seminoma
Retroperitoneal Lymph Node Dissection in Treating Patients With Testicular Seminoma
This phase II trial studies how well retroperitoneal lymph node dissection (RPLND) works in treating patients with stage I-IIa testicular seminoma.
- Conditions
- Lymphadenopathy, Stage I Testicular Seminoma, Stage II Testicular Seminoma
- Trial name
- NCT02537548
- Testing
- Laboratory Biomarker Analysis, Retroperitoneal Lymph Node Dissection
- Where
- 14 sites in United States
- Volunteers
- 55 people
- Sponsor
- University of Southern California
Glioblastoma
A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma
A proof-of-concept clinical trial assessing the safety of the coordinated undermining of survival paths by 9 repurposed drugs combined with metronomic temozolomide (CUSP9v3 treatment protocol) for recurrent glioblastoma
- Trial name
- NCT02770378
- Testing
- Temozolomide, Aprepitant, Minocycline
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- University of Ulm
Solid Tumor, Hepatocellular Carcinoma
NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors
This is a Phase 1, single-arm, single-center, open-label study to evaluate the safety and effectiveness of NKG2D-based CAR-T cells infusion in the treatment of relapsed/refractory NKG2DL+ solid tumors.
- Conditions
- Solid Tumor, Hepatocellular Carcinoma, Colorectal Cancer, Glioma
- Trial name
- NCT04550663
- Testing
- KD-025 CAR-T cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.